ES2347174T3 - Utilizacion de un derivado benzoilo 3-aminocarbazol para el tratamiento de un trastorno asociado a la produccion de la prostaglandina e2 (pge2). - Google Patents
Utilizacion de un derivado benzoilo 3-aminocarbazol para el tratamiento de un trastorno asociado a la produccion de la prostaglandina e2 (pge2). Download PDFInfo
- Publication number
- ES2347174T3 ES2347174T3 ES06753538T ES06753538T ES2347174T3 ES 2347174 T3 ES2347174 T3 ES 2347174T3 ES 06753538 T ES06753538 T ES 06753538T ES 06753538 T ES06753538 T ES 06753538T ES 2347174 T3 ES2347174 T3 ES 2347174T3
- Authority
- ES
- Spain
- Prior art keywords
- production
- pge2
- group
- aminocarbazole
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 208000002193 Pain Diseases 0.000 claims abstract description 10
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000036407 pain Effects 0.000 claims abstract description 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 7
- 206010015150 Erythema Diseases 0.000 claims abstract description 5
- 206010030113 Oedema Diseases 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 231100000321 erythema Toxicity 0.000 claims abstract description 5
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 208000018937 joint inflammation Diseases 0.000 claims abstract description 4
- 230000003449 preventive effect Effects 0.000 claims abstract 4
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 210000001503 joint Anatomy 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 16
- 229960002986 dinoprostone Drugs 0.000 description 14
- 229940127293 prostanoid Drugs 0.000 description 14
- 150000003814 prostanoids Chemical class 0.000 description 14
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 7
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- LRSYZHFYNDZXMU-UHFFFAOYSA-N 9h-carbazol-3-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3NC2=C1 LRSYZHFYNDZXMU-UHFFFAOYSA-N 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 150000001716 carbazoles Chemical class 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100067573 Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440) pgi2 gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 230000002666 vasoprotective effect Effects 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- SGUKUZOVHSFKPH-UHFFFAOYSA-N PGG2 Natural products C1C2OOC1C(C=CC(OO)CCCCC)C2CC=CCCCC(O)=O SGUKUZOVHSFKPH-UHFFFAOYSA-N 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 231100000513 vascular toxicity Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI05A0909 | 2005-05-19 | ||
| IT000909A ITMI20050909A1 (it) | 2005-05-19 | 2005-05-19 | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2347174T3 true ES2347174T3 (es) | 2010-10-26 |
Family
ID=35219704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06753538T Active ES2347174T3 (es) | 2005-05-19 | 2006-05-03 | Utilizacion de un derivado benzoilo 3-aminocarbazol para el tratamiento de un trastorno asociado a la produccion de la prostaglandina e2 (pge2). |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8686021B2 (enExample) |
| EP (1) | EP1881826B1 (enExample) |
| JP (1) | JP5086991B2 (enExample) |
| KR (1) | KR101312579B1 (enExample) |
| CN (1) | CN101166528B (enExample) |
| AR (1) | AR054126A1 (enExample) |
| AT (1) | ATE473739T1 (enExample) |
| AU (1) | AU2006246688B2 (enExample) |
| BR (1) | BRPI0609718A2 (enExample) |
| CA (1) | CA2604562C (enExample) |
| DE (1) | DE602006015457D1 (enExample) |
| DK (1) | DK1881826T3 (enExample) |
| EA (1) | EA012724B1 (enExample) |
| ES (1) | ES2347174T3 (enExample) |
| GE (1) | GEP20094738B (enExample) |
| IL (1) | IL186072A (enExample) |
| IT (1) | ITMI20050909A1 (enExample) |
| MX (1) | MX2007013491A (enExample) |
| PL (1) | PL1881826T3 (enExample) |
| PT (1) | PT1881826E (enExample) |
| SI (1) | SI1881826T1 (enExample) |
| UA (1) | UA94044C2 (enExample) |
| WO (1) | WO2006122680A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| US8880004B2 (en) | 2009-05-14 | 2014-11-04 | Qualcomm Incorporated | System and method for resolving conflicts between air interfaces in a wireless communication system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| US6399631B1 (en) | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| JP2003507424A (ja) * | 1999-08-26 | 2003-02-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体 |
| DE10125961A1 (de) | 2001-05-29 | 2002-12-12 | Boehringer Ingelheim Int | Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden |
| CA2403307A1 (en) * | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| KR20030042344A (ko) * | 2001-11-22 | 2003-05-28 | 한국생명공학연구원 | 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제 |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| KR100402714B1 (ko) * | 2002-12-23 | 2003-11-13 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
-
2005
- 2005-05-19 IT IT000909A patent/ITMI20050909A1/it unknown
-
2006
- 2006-05-03 CN CN2006800144162A patent/CN101166528B/zh not_active Expired - Fee Related
- 2006-05-03 PL PL06753538T patent/PL1881826T3/pl unknown
- 2006-05-03 EP EP06753538A patent/EP1881826B1/en not_active Not-in-force
- 2006-05-03 PT PT06753538T patent/PT1881826E/pt unknown
- 2006-05-03 MX MX2007013491A patent/MX2007013491A/es active IP Right Grant
- 2006-05-03 DK DK06753538.5T patent/DK1881826T3/da active
- 2006-05-03 KR KR1020077029661A patent/KR101312579B1/ko not_active Expired - Fee Related
- 2006-05-03 WO PCT/EP2006/004348 patent/WO2006122680A1/en not_active Ceased
- 2006-05-03 JP JP2008511591A patent/JP5086991B2/ja not_active Expired - Fee Related
- 2006-05-03 GE GEAP200610441A patent/GEP20094738B/en unknown
- 2006-05-03 DE DE602006015457T patent/DE602006015457D1/de active Active
- 2006-05-03 BR BRPI0609718-9A patent/BRPI0609718A2/pt not_active IP Right Cessation
- 2006-05-03 AT AT06753538T patent/ATE473739T1/de active
- 2006-05-03 SI SI200630781T patent/SI1881826T1/sl unknown
- 2006-05-03 UA UAA200713598A patent/UA94044C2/ru unknown
- 2006-05-03 AU AU2006246688A patent/AU2006246688B2/en not_active Ceased
- 2006-05-03 EA EA200702534A patent/EA012724B1/ru not_active IP Right Cessation
- 2006-05-03 CA CA2604562A patent/CA2604562C/en not_active Expired - Fee Related
- 2006-05-03 US US11/909,393 patent/US8686021B2/en not_active Expired - Fee Related
- 2006-05-03 ES ES06753538T patent/ES2347174T3/es active Active
- 2006-05-17 AR ARP060101981A patent/AR054126A1/es not_active Application Discontinuation
-
2007
- 2007-09-19 IL IL186072A patent/IL186072A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101166528A (zh) | 2008-04-23 |
| EP1881826A1 (en) | 2008-01-30 |
| IL186072A0 (en) | 2008-08-07 |
| CA2604562C (en) | 2013-09-17 |
| ITMI20050909A1 (it) | 2006-11-20 |
| IL186072A (en) | 2012-05-31 |
| PT1881826E (pt) | 2010-08-05 |
| CN101166528B (zh) | 2011-06-15 |
| AU2006246688A1 (en) | 2006-11-23 |
| UA94044C2 (ru) | 2011-04-11 |
| JP2008540591A (ja) | 2008-11-20 |
| JP5086991B2 (ja) | 2012-11-28 |
| KR101312579B1 (ko) | 2013-09-30 |
| KR20080018898A (ko) | 2008-02-28 |
| SI1881826T1 (sl) | 2010-10-29 |
| WO2006122680A1 (en) | 2006-11-23 |
| GEP20094738B (en) | 2009-07-27 |
| MX2007013491A (es) | 2008-01-24 |
| PL1881826T3 (pl) | 2010-12-31 |
| CA2604562A1 (en) | 2006-11-23 |
| AR054126A1 (es) | 2007-06-06 |
| US20080287518A1 (en) | 2008-11-20 |
| BRPI0609718A2 (pt) | 2011-10-18 |
| EP1881826B1 (en) | 2010-07-14 |
| EA012724B1 (ru) | 2009-12-30 |
| DE602006015457D1 (de) | 2010-08-26 |
| HK1119571A1 (en) | 2009-03-13 |
| ATE473739T1 (de) | 2010-07-15 |
| EA200702534A1 (ru) | 2008-04-28 |
| AU2006246688B2 (en) | 2011-09-22 |
| US8686021B2 (en) | 2014-04-01 |
| DK1881826T3 (da) | 2010-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2428226T3 (es) | Compuesto de 3-aminocarbazol, composición farmacéutica que lo contiene y procedimiento para su preparación | |
| US8519005B2 (en) | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy | |
| CN103249408A (zh) | 利用多不饱和长链酮类的类风湿性关节炎治疗 | |
| BRPI0806608A2 (pt) | métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios | |
| HUP0001286A2 (hu) | Karbazol-ecetsavat tartalmazó, kutyák fájdalmának és gyulladásának kezelésére alkalmas gyógyszerkészítmény | |
| CN101506161A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 | |
| ES2345944T3 (es) | Compuestos de 3-aminocarbazol, composicion farmaceutica que contiene los mismos y procedimiento para su preparacion. | |
| PT1303265E (pt) | ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida'' | |
| US20050042282A1 (en) | Methods using proton pump inhibitors | |
| WO2006016695A1 (ja) | Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤 | |
| CN101506160A (zh) | 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药 | |
| ES2347174T3 (es) | Utilizacion de un derivado benzoilo 3-aminocarbazol para el tratamiento de un trastorno asociado a la produccion de la prostaglandina e2 (pge2). | |
| WO2006016689A1 (ja) | Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤 | |
| WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
| TW200406405A (en) | Selective inhibitors of cyclooxygenase-2 | |
| FI107609B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(1-substituoituja pyratsoyyli)-2-oksi-indolijohdannaisten valmistamiseksi | |
| Krowicki | Involvement of hindbrain and peripheral prostanoids in gastric motor and cardiovascular responses to delta-9-tetrahydrocannabinol in the rat | |
| JP2011526618A (ja) | カルシウムイオンチャネルモジュレーターおよびその使用 | |
| RU2336872C2 (ru) | Аннелированные пиррольные соединения как ингибиторы протонового насоса для лечения язвы | |
| HK1119571B (en) | Use of a benzoyl derivative of 3-aminocarbazole in manufacture of a medicament in the treatment of a disorder associated with the production of prostaglandin e2 (pge2) | |
| JP2006021998A (ja) | Ｅｐ２アゴニストを有効成分とする月経困難症治療剤 | |
| TW379220B (en) | Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant | |
| US20080234325A1 (en) | Novel Methods Using Pyridine Derivatives | |
| Raju et al. | Cyclooxygenase inhibitors | |
| Chetty Raju et al. | Cyclooxygenase inhibitors |